The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients

Last updated: January 8, 2012
Sponsor: Daewoong Pharmaceutical Co. LTD.
Overall Status: Trial Status Unknown

Phase

4

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT01397240
DW_ABS002P
  • Ages 20-80
  • All Genders

Study Summary

The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female, aged 20 to 80 years

  • Subjects identified with at least one of the following diagnosis (Angina, MyocardialInfarction(Old), Cerebrovascular Disease, Peripheral Vascular Disease, Diabetes,Hypertension, Hypercholeseterolemia, Obesity) who are required to take a low dose ofAspirin (100mg/day) for more than 12 weeks.

Exclusion

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning a pregnancy during the study period orfemales of childbearing potential

  • Peptic ulcer or Reflux oesophagitis

  • hemostatic disorder or coagulation disorder

  • Known allergy or hypersensitivity to the study medication

Study Design

Total Participants: 80
Study Start date:
July 01, 2011
Estimated Completion Date:
June 30, 2013

Study Description

The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients taking Low-dose Aspirin, A pilot study Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel, Prospective study

Connect with a study center

  • Gangnam severance Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.